Details for New Drug Application (NDA): 205248
✉ Email this page to a colleague
NDA 205248 describes NATEGLINIDE, which is a drug marketed by Alvogen, Cadila Pharms Ltd, Dr Reddys Labs Ltd, Rising, Strides Pharma, Teva Pharms, Watson Labs, and Zydus Pharms, and is included in eight NDAs. It is available from eleven suppliers. Additional details are available on the NATEGLINIDE profile page.
The generic ingredient in NATEGLINIDE is nateglinide. There are nine drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the nateglinide profile page.
The generic ingredient in NATEGLINIDE is nateglinide. There are nine drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the nateglinide profile page.
Summary for 205248
| Tradename: | NATEGLINIDE |
| Applicant: | Zydus Pharms |
| Ingredient: | nateglinide |
| Patents: | 0 |
Pharmacology for NDA: 205248
| Mechanism of Action | Potassium Channel Antagonists |
Suppliers and Packaging for NDA: 205248
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| NATEGLINIDE | nateglinide | TABLET;ORAL | 205248 | ANDA | Zydus Pharmaceuticals USA Inc. | 68382-721 | 68382-721-01 | 100 TABLET, FILM COATED in 1 BOTTLE (68382-721-01) |
| NATEGLINIDE | nateglinide | TABLET;ORAL | 205248 | ANDA | Zydus Pharmaceuticals USA Inc. | 68382-721 | 68382-721-05 | 500 TABLET, FILM COATED in 1 BOTTLE (68382-721-05) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 60MG | ||||
| Approval Date: | Jul 6, 2016 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 120MG | ||||
| Approval Date: | Jul 6, 2016 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
